Comparative effects of selective and non-selective sodium–glucose cotransporter inhibition on cognitive dysfunction in a rat model of type 2 diabetes
Abstract
Type 2 diabetes mellitus (T2DM) is increasingly recognized as a major risk factor for cognitive decline and Alzheimer’s disease (AD), yet the therapeutic potential of antidiabetic agents on diabetes-associated neurodegeneration remains incompletely understood. In this study, we investigated the effects of the non-selective sodium–glucose cotransporter (SGLT) inhibitor phlorizin and the selective SGLT2 inhibitor dapagliflozin on metabolic parameters and cognitive performance in a rat model of T2DM-related cognitive dysfunction (T2DM-CD). Male Sprague–Dawley rats were fed a high-fat diet and administered low-dose streptozotocin to induce a diabetic phenotype accompanied by cognitive impairment. Animals were treated for four weeks with dapagliflozin, phlorizin, metformin, or rivastigmine. Blood glucose levels, body weight, locomotor activity, and recognition memory were assessed using standardized metabolic and behavioural tests. The T2DM-CD model exhibited sustained hyperglycaemia and significant impairment in recognition memory without alterations in locomotor activity. Treatment with dapagliflozin and phlorizin significantly reduced blood glucose levels and markedly improved recognition memory compared with untreated animals. Rivastigmine also improved cognitive performance without affecting glycaemic control, whereas metformin produced only modest cognitive benefits. None of the treatments significantly altered body weight. These findings demonstrate that SGLT inhibition…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.